💊 Ajanta Pharma Rallies as Profit, Revenue Beat Expectations

shares rallied over 6.5% by 12:10 PM on May 6, 2026, following its Q4 results, reflecting a positive market response. The company reported a net profit of ₹267 crore, marking an 18.7% YoY increase from ₹225 crore. Revenue rose 21.5% to ₹1,422 crore, while EBITDA grew 12.1% to ₹333 crore. However, EBITDA margin softened to 23.4% from 25.4%. On the price front, the stock opened with a gap-up and continued to witness steady follow-through buying during the session, indicating sustained demand post earnings announcement. The upward move in price action aligns with the strong top-line and profit growth reported in the quarterly performance. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.